<?xml version="1.0" encoding="UTF-8"?>
<p>The primary endpoint, MDS-UPDRS Part III score, decreased significantly from before the treatment to the 57th day of the medication (Pre = 28.1 ± 9.3; Post = 24.7 ± 10.8; mean ± SD; 
 <italic>P</italic> = .0146 by paired t test) (Fig. 
 <xref ref-type="fig" rid="F2">2</xref>; Table 
 <xref rid="T2" ref-type="table">2</xref>). The change of the mean value was −3.4, which fulfilled a previously established criteria for the minimal clinically important difference for MDRS-UPDRS Part III score of −3.25.
 <sup>[
  <xref rid="R49" ref-type="bibr">49</xref>]
 </sup> Analysis using the Wilcoxon signed-rank sum test also showed a significant difference of 
 <italic>P</italic> = .0193.
</p>
